Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY

Value in Health ◽

10.1016/s1098-3015(10)70446-0 ◽

2008 ◽

Vol 11 (3) ◽

pp. A140 ◽

Cited By ~ 1

Author(s):

R Gani ◽

ER Samuels ◽

S Hughes ◽

G Giovanonni

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

Value in Health ◽

10.1016/s1098-3015(11)70789-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 362-363

Author(s):

E Orlewska ◽

P Mierzejewski ◽

A Czlonkowska

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States

Value in Health ◽

10.1016/j.jval.2018.04.1400 ◽

2018 ◽

Vol 21 ◽

pp. S206

Author(s):

D Rao ◽

E Heidari ◽

KM Kamal ◽

AA Dashputre

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

10.1002/14651858.cd009333 ◽

2011 ◽

Author(s):

Loredana La Mantia ◽

Alberto Vaona ◽

Marco Rovaris ◽

Francesco Berardo ◽

Serena Frau ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

Applied Health Economics and Health Policy ◽

10.1007/bf03256144 ◽

2009 ◽

Vol 7 (2) ◽

pp. 91-108 ◽

Cited By ~ 25

Author(s):

Stephanie R. Earnshaw ◽

Jonathan Graham ◽

MerriKay Oleen-Burkey ◽

Jane Castelli-Haley ◽

Kenneth Johnson

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Relapsing Remitting ◽

Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Glatiramer Acetate and Interferon Beta (PD5.008)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.pd5.008 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. PD5.008-PD5.008

Author(s):

G. Rojas ◽

C. Vrech ◽

F. Leguizamon ◽

S. Lindembaum ◽

A. Carra

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Clinical Predictors ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Free Status

A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn31557558 ◽

2013 ◽

Author(s):

Mike Boggild

Keyword(s):

Multiple Sclerosis ◽

Randomised Controlled Trial ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Controlled Trial ◽

Sequential Treatment ◽

Relapsing Remitting ◽

Randomised Controlled ◽

Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.3111/200104207219 ◽

2001 ◽

Vol 4 (1-4) ◽

pp. 207-219 ◽

Cited By ~ 9

Author(s):

Uday Bose ◽

David Ladkani ◽

Anita Burrell ◽

Mohammad Sharief

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

PNP15: COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)64043-0 ◽

2003 ◽

Vol 6 (3) ◽

pp. 277

Author(s):

C Rubio-Terrés ◽

F Medina ◽

I Aristegui ◽

G Izquierdo

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽